(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
How to watch ‘The Traitors’ U.K. Season 4 from the U.S. - 2Artemis II astronauts arrive in Florida to prepare for launch to the moon
- 3Manual for Picking Coastline Travel
- 4How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- 5Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- Civilian toll mounts in Iran as war presses on
- South African army arrive in crime hotspots to help tackle gangs
- Discovery of massive spider's web in Greece reveals unexpected behavior
- EU top diplomat Kallas arrives in Kiev to commemorate Bucha massacre
- Allow Innovative Progressions To have a Massive Effect
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
